Investors bet on newer technology and indications for CGTs
As confidence grows for innovative in vivo strategies, some investors are saying they could be the future of the cell …
Post
-
-
FDA awards record number of review designations to ADCs in 2024
Antibody drug conjugates (ADCs) have gained significant momentum in recent years, due to their clinical successes in cancer treatment. Since …
-
AstraZeneca to expand biomanufacturing in Maryland, US
AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in the US state of Maryland, aiming to …
-
The rise of large-volume injectors: Patient-centric innovation in biologics delivery
For decades, intravenous (IV) infusions in clinical settings were the standard for therapies such as monoclonal antibodies. Today, advances in …
-
Vaximm and BCME link on oral cancer immunotherapy platform
OSR Company Vaximm has signed a non-binding term sheet with Swiss-based life sciences investor BCM Europe (BCME) for a potential …
-
Galapagos CEO tightens strategic focus in pursuit of key assets
For many observers, Galapagos is in an enviable position. The biotech has a balance sheet of €3bn to call upon …
-
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
The Centers for Disease Control and Prevention (CDC) has updated its website to state that there could be a link …
-
Early planning, outsourcing and digitalisation to break down CGT CMC barriers
Since their inception, cell and gene therapies (CGTs) have shown great promise in treating a plethora of challenging diseases. Despite their …
-
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead …
-
Alvotech and Advanz announce EC approval for Gobivaz biosimilar
Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across …
-
CPHI 2025: linker innovation paves the way for a wave of new ADCs
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door …
-
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
Merck KGaA has signed a drug discovery partnership with Valo Health, becoming the latest big pharma to enlist the services …
-
Moderna to onshore drug product manufacturing to Massachusetts
Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology …
-
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its …
-
Novartis taps North Carolina as new manufacturing hub location
Novartis has settled on North Carolina as the home for three of its newest manufacturing facilities, which will see the …
